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Bordetella pertussis and Bordetella parapertussis are the
etiologic agents of whooping cough or pertussis, a respiratory
disease that is most severe in infants and young children.
Compared to B. pertussis, B. parapertussis is isolated less
frequently from pertussis patients (1% to 5% of pertussis
patients in The Netherlands) and generally causes less severe
symptoms. Pertussis is highly contagious, and, in the
prevaccination era, nearly every child contracted this disease.
The clinical course of pertussis is characterized by paroxysms,
or bursts, of numerous, rapid coughs followed by a long
inspiratory effort, which may be accompanied by a
characteristic high-pitched whoop (hence the designation
whooping cough). During such an attack, patients may turn
blue due to lack of oxygen. In serious cases, this oxygen
deprivation may lead to brain damage. The most common
complication of pertussis, however, is secondary pneumonia.
Young infants are at highest risk for pertussis-associated
complications. More than 50% of infants less than 6 months old
who contract pertussis require hospitalization. Treatment of
pertussis is primarily supportive, and adequate control of the
disease depends on effective immunization. Before vaccination
was introduced in the 1950s, pertussis was a major cause of
infant death throughout the world (1). Widespread vaccination of
young children has been successful in controlling the disease (1).
Vaccination
The high rate of illness and death caused by pertussis
stimulated the early development of vaccines composed of whole,
killed bacteria. These whole-cell vaccines were introduced in
many countries in the 1950s and 1960s and have been highly
successful in reducing the incidence of pertussis (1). The desire to
avoid the side effects of whole-cell vaccines has stimulated the
development of less reactogenic, acellular, vaccines composed of
purified  B. pertussis proteins (2). Acellular vaccines are
replacing whole-cell vaccines in many countries.
Despite vaccination, pertussis is an endemic disease.
Various sero-epidemiologic studies have shown that the
frequency of infection may be as high as 1% to 4% (de Melker and
Schellekens, pers. comm.) (3). Further up to 30% of people with
a persistent cough were found to have been infected with B.
pertussis (4). It is possible that vaccination initially reduced the
circulation of B. pertussis and that adaptation allowed the B.
pertussis population to restore its high circulation rate. This
assumption predicts a change in the makeup of the B. pertussis
population after the introduction of vaccination, a phenomenon
that has indeed been observed in The Netherlands.
Changes in B. pertussis in a Highly Vaccinated
Population
In some countries with highly vaccinated populations such
as Australia (5), Canada (6), and The Netherlands (7) (Figure 1),
pertussis has reemerged. Such a phenomenon may have been
caused by changes in the accuracy of notifications, decreases in
vaccine coverage, or changes in vaccine quality. These
possibilities have been excluded for The Netherlands (7), and we
have proposed another possible cause: adaptation of B. pertussis
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In the Netherlands, as in many other western countries, pertussis vaccines have
been used extensively for more than 40 years. Therefore, it is conceivable that
vaccine-induced immunity has affected the evolution of Bordetella pertussis.
Consistent with this notion, pertussis has reemerged in the Netherlands, despite
high vaccination coverage. Further, a notable change in the population structure
of B. pertussis was observed in the Netherlands subsequent to the introduction
of vaccination in the 1950s. Finally, we observed antigenic divergence between
clinical isolates and vaccine strains, in particular with respect to the surface-
associated proteins pertactin and pertussis toxin. Adaptation may have allowed
B. pertussis to remain endemic despite widespread vaccination and may have
contributed to the reemergence of pertussis in the Netherlands.
Figure 1. Notifications of pertussis in the Netherlands.
Source: National Institute of Public Health and the Environment527 Vol. 7, No. 3 Supplement, June 2001 Emerging Infectious Diseases
Conference Presentations
to the vaccine. To investigate this hypothesis, B. pertussis strains
collected in The Netherlands from 1949 to 1996 were
characterized by DNA fingerprinting and sequencing of genes
coding for surface proteins (8,9).
Initially, we studied changes in the B. pertussis
population by IS1002-based DNA fingerprinting (9,10).
Strains collected from 1949 to 1996 were stratified in periods
of 5 to 8 years, and the frequency of fingerprint types in each
period was determined (Figure 2). Widespread vaccination
was introduced in The Netherlands in 1953, and we assumed
that the B. pertussis population was not significantly affected
by vaccination from 1949 to 1954 (defined as the
prevaccination period in Figure 2). Notable differences were
found between the populations from the prevaccination era
and the subsequent period, both in the type and frequency of
fingerprint types (e.g., the major fingerprint type found in
strains collected from 1965-1972 [Ft-29] was absent during
the prevaccination period). These qualitative observations
were confirmed by the trend in genotypic diversity (Figure 2).
Genotypic diversity decreased significantly after the
introduction of vaccination and subsequently increased to
prevaccination levels. In the 1980s, a second decrease in
genotypic diversity occurred. Apart from sampling artifacts, a
drop in genotypic diversity may be caused by a decrease in
population size or clonal expansion. Indeed, we found that the
reduction in genotypic diversity in the 1960s and 1980s was
associated with the expansion of antigenically distinct strains.
In a second study of changes in the B. pertussis
population, we investigated whether antigenic shifts had
occurred in surface proteins (8). Very little polymorphism was
observed in most proteins studied. However, two virulence
factors, pertussis toxin and pertactin, were polymorphic.
Interestingly, antibodies against these proteins correlate
with protection against disease, which suggests they have an
important role in inducing host immunity (12,13).
Essentially, all DNA polymorphisms observed were noncon-
servative, indicating Darwinian selection. Three pertactin
and three pertussis toxin variants were found in the Dutch
B. pertussis population (Figure 3). Polymorphism in pertussis
toxin was restricted to the S1 subunit (PtxS1), which carries
the toxic activity. Variation in PtxS1 was observed in two
regions. Significantly, one of the polymorphic residues has
been implicated in binding to the T-cell receptor (14).
Polymorphism in pertactin was confined to a region
comprised of tandem repeats located proximally to the RGD
motif involved in adherence to host tissues (15). Regions with
tandem repeats are known to undergo rapid variation due to
slipped-strand mispairing during replication (16). Pertactin and
PtxS1 variants, identical to those included in the Dutch whole-
cell vaccine, were found in 100% of the strains from the 1950s,
when the whole-cell vaccine was introduced in The Netherlands
(Figure 4). However, nonvaccine types of pertactin and PtxS1
gradually replaced the vaccine types in later years and were
found in 90% of strains collected from 1990 to 1996. These results
suggest that vaccination has caused strains that are
antigenically distinct from vaccine strains to be selected. The
drop in genotypic diversity observed in the 1960s and the 1980s
coincided with the emergence of nonvaccine-type pertussis toxin
and pertactin variants, respectively, suggesting that the drop
was caused by clonal expansion. Antigenic divergence between
vaccine strains and clinical isolates was also observed in other
Figure 2. Changes in the population structure of B. pertussis in The
Netherlands as determined by IS1002-based DNA fingerprinting.
Strains isolated from Dutch patients from 1949 to 1996 were
stratified in periods of 5 to 8 years. The frequency of fingerprint types
(Ft) in each period was determined and is displayed by colored bars.
Genotypic diversity was calculated according to Nei, using
fingerprint data (11). Adapted from (10).
Figure 4. Temporal trends in frequencies of pertussis toxin and
pertactin variants in The Netherlands.
Figure 3. Polymorphism in pertactin (Prn) and the S1 subunit of
pertussis (PtxS1) toxin found in Dutch strains. The RGD sequence in
pertactin, involved in binding to host receptors, has been underlined.
Dashes indicate gaps. Numbers refer to positions of amino acids
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countries with a long history of pertussis vaccination, such as
Finland and the United States (17,18), and also in Italy, where
vaccine coverage has varied considerably.
Discussion
Is polymorphism in pertactin and pertussis toxin driven by
host immunity, or is it the result of random fixation due to
genetic drift? The latter possibility is highly unlikely since
essentially all DNA mutations we detected in the pertactin and
pertussis toxin genes were nonconservative. In contrast, random
genetic drift is characterized by a high degree of conservative
mutations in protein coding regions (20). Further, the
polymorphic regions interact directly with the immune system.
The polymorphic region of pertactin induces a protective
immune response (unpublished data). One of the polymorphic
residues in PtxS1 has been implicated in binding to the T-cell
receptor (14). Finally, the fact that the same temporal trends in
allele frequencies are observed in geographically distinct regions
such as Finland, the United States, and The Netherlands argues
against random genetic drift. It is possible that the polymorphic
loci we have identified are linked to other, as yet unknown,
polymorphic loci that increase fitness of strains in vaccinated
populations (hitchhiking).
Strains carrying nonvaccine-type pertactin or pertussis
toxin variants were not found in the prevaccination era.
Although the number of strains analyzed from this period was
limited, these data suggest that the nonvaccine-type variants
are not able to displace the vaccine-type strains in
unvaccinated populations (i.e., they have a lower fitness level,
or reproductive rate, in unvaccinated communities).
Alternatively, the nonvaccine-type strains may have evolved
relatively recently. Consistent with the first hypothesis, we
have observed that nonvaccine-type strains are less fit in
naive mice than vaccine-type strains. In immune mice the
difference in fitness between the two types of strains was
much less pronounced (unpublished data). Thus vaccination
has acted to shift the competitive balance between strains.
An important question to address is whether adaptation of
the B. pertussis population has affected vaccine efficacy, i.e.,
contributed to the reemergence of B. pertussis. Animal
experiments have indicated that variation in pertactin affects
vaccine efficacy (unpublished data). Further, we found vaccine-
type pertactin variants less frequently among vaccinated
persons than among unvaccinated persons, which would be
expected if the vaccine protects differentially against strains
with distinct pertactin types (8). However, the extent to which
polymorphism affects vaccine efficacy is probably dependent on
the vaccine used. It is conceivable that the increase in fitness
associated with nonvaccine types of pertactin and pertussis toxin
in vaccinated populations is substantial enough to drive
expansion of strains carrying these protein variants but that the
effect is too small to result in a measurable drop in vaccine
efficacy. Further studies are required to assess the effect of the
observed adaptations on the efficacy of pertussis vaccines. In this
period, when whole-cell vaccines are being replaced by acellular
vaccines in many countries, continued strain surveillance is of
paramount importance.
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